Protein overexpression and gene amplification of epidermal growth factor receptor in nonsmall cell lung carcinomas: Comparison of four commercially available antibodies by immunohistochemistry and fluorescence in situ hybridization study

Lung Cancer

Volumn 68, Issue 3, 2010, Pages 375-382

  Lee, Hyun Ju ^a   Xu, Xianhua ^a   Choe, Gheeyoung ^a   Chung, Doo Hyun ^a   Seo, Jeong Wook ^a   Lee, Jae Ho ^a   Lee, Choon Taek ^a,b   Jheon, Sanghoon ^a,b   Sung, Sook Whan ^a,b   Chung, Jin Haeng ^a,b  

^a Seoul National University College of Medicine   (South Korea)

^b Seoul National University Bundang Hospital   (South Korea)

Author keywords

EGFR; FISH; Immunohistochemistry; Lung neoplasm

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; ANTIBODY; DIAGNOSTIC KIT;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE DOSAGE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MOLECULAR CLONING; PRIORITY JOURNAL; PROTEIN EXPRESSION; CARCINOMA, NON-SMALL-CELL LUNG; COMMERCIAL PHENOMENA; COMPARATIVE STUDY; DIAGNOSTIC KIT; GENETICS; IMMUNOLOGY; LUNG NEOPLASMS; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; PROGNOSIS; SENSITIVITY AND SPECIFICITY;

ANTIBODIES; CARCINOMA, NON-SMALL-CELL LUNG; COMMERCE; GENE AMPLIFICATION; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; LUNG NEOPLASMS; PROGNOSIS; REAGENT KITS, DIAGNOSTIC; RECEPTOR, EPIDERMAL GROWTH FACTOR; SENSITIVITY AND SPECIFICITY;

EID: 77952548502     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2009.07.014     Document Type: Article

References (46)

1. Nicholson R.I., Gee J.M., Harper M.E. EGFR and cancer prognosis. Eur J Cancer 2001, 37(Suppl. 4):S9-S15.
2. Pao W., Miller V., Zakowski M., et al. EGF receptor gene mutations are common in lung cancers from " never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 2004, 101:13306-13311.
3. Tsao M.S., Sakurada A., Cutz J.C., et al. Erlotinib in lung cancer-molecular and clinical predictors of outcome. N Engl J Med 2005, 353:133-144.
4. Cappuzzo F., Hirsch F.R., Rossi E., et al. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer Inst 2005, 97:643-655.
5. Hirsch F.R., Varella-Garcia M., McCoy J., et al. Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: a Southwest Oncology Group Study. J Clin Oncol 2005, 23:6838-6845.
6. Prudkin L., Wistuba I.I. Epidermal growth factor receptor abnormalities in lung cancer. Pathogenetic and clinical implications. Ann Diagn Pathol 2006, 10:306-315.
7. Tokumo M., Toyooka S., Kiura K., et al. The relationship between epidermal growth factor receptor mutations and clinicopathologic features in non-small cell lung cancers. Clin Cancer Res 2005, 11:1167-1173.
8. Taron M., Ichinose Y., Rosell R., et al. Activating mutations in the tyrosine kinase domain of the epidermal growth factor receptor are associated with improved survival in gefitinib-treated chemorefractory lung adenocarcinomas. Clin Cancer Res 2005, 11:5878-5885.
9. Paez J.G., Janne P.A., Lee J.C., et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004, 304:1497-1500.
10. Lynch T.J., Bell D.W., Sordella R., et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004, 350:2129-2139.
11. Hirsch F.R., Varella-Garcia M., Bunn P.A., et al. Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. J Clin Oncol 2003, 21:3798-3807.
12. Takano T., Ohe Y., Sakamoto H., et al. Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer. J Clin Oncol 2005, 23:6829-6837.
13. Hirsch F.R., Scagliotti G.V., Langer C.J., et al. Epidermal growth factor family of receptors in preneoplasia and lung cancer: perspectives for targeted therapies. Lung Cancer 2003, 41(Suppl. 1):S29-S42.
14. Franklin W.A., Veve R., Hirsch F.R., et al. Epidermal growth factor receptor family in lung cancer and premalignancy. Semin Oncol 2002, 29:3-14.
15. Jeon Y.K., Sung S.W., Chung J.H., et al. Clinicopathologic features and prognostic implications of epidermal growth factor receptor (EGFR) gene copy number and protein expression in non-small cell lung cancer. Lung Cancer 2006, 54:387-398.
16. Nakamura H., Kawasaki N., Taguchi M., et al. Survival impact of epidermal growth factor receptor overexpression in patients with non-small cell lung cancer: a meta-analysis. Thorax 2006, 61:140-145.
17. Suzuki S., Dobashi Y., Sakurai H., et al. Protein overexpression and gene amplification of epidermal growth factor receptor in nonsmall cell lung carcinomas. An immunohistochemical and fluorescence in situ hybridization study. Cancer 2005, 103:1265-1273.
18. Lee S., Choi J., Jang S.J. Clinicopathologic analysis of epidermal growth factor receptor status in non-small cell lung cancer: protein expression, gene amplification and survival analysis. Korean J Pathol 2007, 41:387-392.
19. Yoo J., Lee K., Jung J.H., et al. Protein expression and gene amplification of epidermal growth factor receptor in non-small cell lung cancer: correlation with the response to gefitinib therapy. Korean J Pathol 2008, 42:1-8.
20. Seok Sh, Kim M.J. Epidermal growth factor receptor expression of non-small cell carcinoma and its relationship with genomic mutation. Korean J Pathol 2008, 42:94-99.
21. Sasaki H., Endo K., Okuda K., et al. Epidermal growth factor receptor gene amplification and gefitinib sensitivity in patients with recurrent lung cancer. J Cancer Res Clin Oncol 2008, 134:569-577.
22. Reinmuth N., Jauch A., Xu E.C., et al. Correlation of EGFR mutations with chromosomal alterations and expression of EGFR, ErbB3 and VEGF in tumor samples of lung adenocarcinoma patients. Lung Cancer 2008, 62(2):193-201.
23. Pinter F., Papay J., Almasi A., et al. Epidermal growth factor receptor (EGFR) high gene copy number and activating mutations in lung adenocarcinomas are not consistently accompanied by positivity for EGFR protein by standard immunohistochemistry. J Mol Diagn 2008, 10:160-168.
24. Li A.R., Chitale D., Riely G.J., et al. EGFR mutations in lung adenocarcinomas: clinical testing experience and relationship to EGFR gene copy number and immunohistochemical expression. J Mol Diagn 2008, 10:242-248.
25. Hirsch F.R., Dziadziuszko R., Thatcher N., et al. Epidermal growth factor receptor immunohistochemistry: comparison of antibodies and cutoff points to predict benefit from gefitinib in a phase 3 placebo-controlled study in advanced nonsmall-cell lung cancer. Cancer 2008, 112:1114-1121.
26. Felip E., Rojo F., Reck M., et al. A phase II pharmacodynamic study of erlotinib in patients with advanced non-small cell lung cancer previously treated with platinum-based chemotherapy. Clin Cancer Res 2008, 14:3867-3874.
27. Ahn M.J., Park B.B., Ahn J.S., et al. Are there any ethnic differences in molecular predictors of erlotinib efficacy in advanced non-small cell lung cancer?. Clin Cancer Res 2008, 14:3860-3866.
28. Wei E.X., Anga A.A., Martin S.S., et al. EGFR expression as an ancillary tool for diagnosing lung cancer in cytology specimens. Mod Pathol 2007, 20:905-913.
29. Hirsch F.R., Varella-Garcia M., Cappuzzo F., et al. Combination of EGFR gene copy number and protein expression predicts outcome for advanced non-small-cell lung cancer patients treated with gefitinib. Ann Oncol 2007, 18:752-760.
30. Cappuzzo F., Ligorio C., Janne P.A., et al. Prospective study of gefitinib in epidermal growth factor receptor fluorescence in situ hybridization-positive/phospho-Akt-positive or never smoker patients with advanced non-small-cell lung cancer: the ONCOBELL trial. J Clin Oncol 2007, 25:2248-2255.
31. Italiano A., Vandenbos F.B., Otto J., et al. Comparison of the epidermal growth factor receptor gene and protein in primary non-small-cell-lung cancer and metastatic sites: implications for treatment with EGFR-inhibitors. Ann Oncol 2006, 17:981-985.
32. Hirsch F.R., Varella-Garcia M., Bunn P.A., et al. Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer. J Clin Oncol 2006, 24:5034-5042.
33. Shepherd F.A., Rodrigues Pereira J., Ciuleanu T., et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005, 353:123-132.
34. Han S.W., Hwang P.G., Chung D.H., et al. Epidermal growth factor receptor (EGFR) downstream molecules as response predictive markers for gefitinib (Iressa, ZD1839) in chemotherapy-resistant non-small cell lung cancer. Int J Cancer 2005, 113:109-115.
35. Awaya H., Takeshima Y., Furonaka O., et al. Gene amplification and protein expression of EGFR and HER2 by chromogenic in situ hybridisation and immunohistochemistry in atypical adenomatous hyperplasia and adenocarcinoma of the lung. J Clin Pathol 2005, 58:1076-1080.
36. Parra H.S., Cavina R., Latteri F., et al. Analysis of epidermal growth factor receptor expression as a predictive factor for response to gefitinib ('Iressa' ZD1839) in non-small-cell lung cancer. Br J Cancer 2004, 91:208-212.
37. Atkins D., Reiffen K.A., Tegtmeier C.L., et al. Immunohistochemical detection of EGFR in paraffin-embedded tumor tissues: variation in staining intensity due to choice of fixative and storage time of tissue sections. J Histochem Cytochem 2004, 52:893-901.
38. Ahn J.H., Kim S.W., Hong S.M., et al. Epidermal growth factor receptor (EGFR) expression in operable non-small cell lung carcinoma. J Korean Med Sci 2004, 19:529-535.
39. Meert A.P., Martin B., Delmotte P., et al. The role of EGF-R expression on patient survival in lung cancer: a systematic review with meta-analysis. Eur Respir J 2002, 20:975-981.
40. Dziadziuszko R., Hirsch F.R., Varella-Garcia M., et al. Selecting lung cancer patients for treatment with epidermal growth factor receptor tyrosine kinase inhibitors by immunohistochemistry and fluorescence in situ hybridization-why, when, and how?. Clin Cancer Res 2006, 12:s4409-s4415.
41. Selvaggi G., Novello S., Torri V., et al. Epidermal growth factor receptor overexpression correlates with a poor prognosis in completely resected non-small-cell lung cancer. Ann Oncol 2004, 15:28-32.
42. Niemiec J., Kolodziejski L., Dyczek S., et al. Prognostic significance of epidermal growth factor receptor in surgically treated squamous cell lung cancer patients. Folia Histochem Cytobiol 2004, 42:111-118.
43. Travis W.D., Brambilla E., Muller-Hermelink H.K., et al. World Health Organization classification of tumours. Pathology and genetics of tumours of the lung, pleura, thymus and heart 2004, IARC Press, Lyon.
44. Han S.W., Kim T.Y., Jeon Y.K., et al. Optimization of patient selection for gefitinib in non-small cell lung cancer by combined analysis of epidermal growth factor receptor mutation, K-ras mutation, and Akt phosphorylation. Clin Cancer Res 2006, 12:2538-2544.
45. Dacic S., Flanagan M., Cieply K., et al. Significance of EGFR protein expression and gene amplification in non-small cell lung carcinoma. Am J Clin Pathol 2006, 125:860-865.
46. Sequist L.V., Haber D.A., Lynch T.J. Epidermal growth factor receptor mutations in non-small cell lung cancer: predicting clinical response to kinase inhibitors. Clin Cancer Res 2005, 11:5668-5670.